Publicacións en colaboración con investigadores/as de Universidad Pública de Navarra (21)

2024

  1. Impact of a longitudinal course on medical professionalism on the empathy of medical students

    Patient Education and Counseling, Vol. 119

  2. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2023

  1. Co-Design and Validation of a Family Nursing Educational Intervention in Long-Term Cancer Survivorship Using Expert Judgement

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 2

  2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  3. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

    British Journal of Cancer, Vol. 126, Núm. 8, pp. 1168-1177

  4. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

    Theranostics, Vol. 12, Núm. 3, pp. 1373-1387

2021

  1. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  2. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

  3. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  4. Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

  5. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

  6. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?

    Frontiers in Cell and Developmental Biology, Vol. 9

  7. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge

    Frontiers in Immunology, Vol. 12

  8. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10

  9. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. Binge drinking and risk of breast cancer: Results from the SUN (‘Seguimiento universidad de Navarra’) project

    Nutrients, Vol. 12, Núm. 3

  2. PD-L1 in systemic immunity: Unraveling its contribution to PD-1/PD-L1 blockade immunotherapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 16, pp. 1-17

  3. Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies

    International Journal of Molecular Sciences, Vol. 21, Núm. 7